NCT00758251
Completed
Not Applicable
Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
ConditionsSchizophrenia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- AstraZeneca
- Enrollment
- 80
- Locations
- 2
- Primary Endpoint
- Improvement in CGI scores and BPRS comparing visits 1 and 3.
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
- •Signed and dated Patient Informed Consent (ICF)
Exclusion Criteria
- •Hypersensitivity to the active substance or to any of the excipients of Seroquel XR
Outcomes
Primary Outcomes
Improvement in CGI scores and BPRS comparing visits 1 and 3.
Time Frame: twice with 4 week interval
Secondary Outcomes
- To evaluate compliance to therapy(twice with 4 week interval)
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
NIS to Observe Improvement in Global Assessment of Functioning in Patients With SchizophreniaSchizophreniaNCT00833456AstraZeneca106
Completed
Phase 4
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic DrugsSchizoaffective DisorderSchizophreniaNCT00649064Pfizer's Upjohn has merged with Mylan to form Viatris Inc.46
Completed
Phase 4
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsSchizophreniaNCT04940039Janssen-Cilag International NV93
Completed
Not Applicable
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in PortugalSchizophreniaNCT03666715Janssen-Cilag Farmaceutica Ltda.55
Completed
Not Applicable
FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in SpainSchizophreniaNCT01376492Janssen-Cilag, S.A.709